Publications scientifiques en oncologie
Long-Term Efficacy, Safety and PK Data of TH1902 (Sudocetaxel Zendusortide) in Solid Tumors: A Novel SORT1-Targeting Peptide-Drug Conjugate (PDC)
2024
Ira Winer MD, Minal Barve MD, Satish Shah MD, Manish Sharma MD, Christian Marsolais, Michel Demeule, Kathya Daigle, Lynn Douglas, Funda Meric-Bernstam MD
Pre-clinical evidence for new camptothecin-peptide conjugates in the treatment of sortilin-positive colorectal cancers
2024
Sanjoy Kumar Das, Jean-Christophe Currie, Michel Demeule, Cyndia Charfi, Alain Zgheib, Amit Nayyar, Anh Minh Thao Nguyen, Bogdan Alexandru Danalache, Richard Béliveau, Christian Marsolais, Borhane Annabi
Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing
2024
Michel Demeule, Jean-Christophe Currie, Cyndia Charfi, Alain Zgheib, Isabelle Cousineau, Véronique Lullier, Richard Béliveau, Christian Marsolais, Borhane Annabi
Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study
2023
Funda Meric-Bernstam, Satish Shah, Manish Sharma, Annick Metcalfe, Guylaine Roy, Lynn Marie Douglas, Christian Marsolais, Ira Seth Winer
The peptide-drug conjugate sudocetaxel zendusortide (TH1902) potentiates anti-tumoral activity of the anti-PD-L1 checkpoint inhibitor and induces immune cell infiltration in a B16-F10 syngeneic melanoma model
2023
Michel Demeule, Jean-Christophe Currie, Cyndia Charfi, Alain Zgheib, Isabelle Cousineau, Richard Béliveau, Christian Marsolais, Borhane Annabi